Department of Neurology, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Medicine (Baltimore). 2024 Mar 1;103(9):e37495. doi: 10.1097/MD.0000000000037495.
To explore the efficacy and safety of butylphthalide combined with idebenone in the treatment of vascular dementia. The clinical data of 126 patients with vascular dementia who were admitted to our hospital between March 2021 and February 2023 were retrospectively reviewed. Among them, 62 patients received butylphthalide alone (single group) and 64 patients received butylphthalide combined with idebenone (combined group). Cognitive function scores, serum inflammatory factor levels, oxidative stress index levels, and incidence of adverse reactions were compared between the 2 groups before and after treatment. After treatment, the Hasegawa Dementia Scale, Mini Mental State Examination Scale, and activities of daily living scores in both groups were higher than before treatment, and the scores in the combined group were higher than before treatment (P < .05). After treatment, the levels of serum C-reactive protein, tumor necrosis factor-α, and interleukin 6 in both groups were lower than those before treatment, and those in the combined group were lower than those in the simple group (P < .05). After treatment, the levels of serum glutathione peroxidase and superoxide dismutase in the 2 groups were higher than those before treatment, and the level of malondialdehyde was lower than that before treatment. The levels of serum glutathione peroxidase and superoxide dismutase in the combined group were higher than those in the simple group, and the level of malondialdehyde was lower than that in the simple group (P < .05). There was no significant difference in the incidence of adverse reactions between the combined group (6.25%) and the simple group (3.23%) (P > .05). Compared with butylphthalide alone, intervention of butylphthalide combined with idebenone on vascular dementia can effectively reduce the degree of inflammatory and oxidative stress reactions, improve cognitive function, and promote the ability to perform activities of daily living in a safe manner.
探讨丁苯酞联合依达拉奉治疗血管性痴呆的疗效及安全性。回顾性分析 2021 年 3 月至 2023 年 2 月我院收治的 126 例血管性痴呆患者的临床资料，其中 62 例患者给予丁苯酞治疗（单药组），64 例患者给予丁苯酞联合依达拉奉治疗（联合组）。比较两组患者治疗前后认知功能评分、血清炎症因子水平、氧化应激指标水平及不良反应发生率。治疗后，两组患者的简易智力状态检查量表、日常生活能力量表及 Hasegawa 痴呆量表评分均高于治疗前，且联合组高于单药组（P<0.05）。治疗后，两组患者的血清 C 反应蛋白、肿瘤坏死因子-α、白细胞介素 6 水平均低于治疗前，且联合组低于单药组（P<0.05）。治疗后，两组患者的血清谷胱甘肽过氧化物酶、超氧化物歧化酶水平均高于治疗前，丙二醛水平均低于治疗前；且联合组的血清谷胱甘肽过氧化物酶、超氧化物歧化酶水平高于单药组，丙二醛水平低于单药组（P<0.05）。联合组不良反应发生率（6.25%）与单药组（3.23%）比较差异无统计学意义（P>0.05）。与丁苯酞单药治疗相比，丁苯酞联合依达拉奉干预血管性痴呆能有效减轻炎症和氧化应激反应程度，改善认知功能，且安全性较高，能促进日常生活活动能力的恢复。
